Meeting
2017 Gastrointestinal Cancers Symposium
Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.
Authors
Courtney C Cavalieri
Huntsman Cancer Institute, Salt Lake City, UT
Courtney C Cavalieri , Eric Swanson , Jonathan R. Whisenant , John R. Weis , Glynn Weldon Gilcrease , David D. Stenehjem , Sunil Sharma , Ignacio Garrido-Laguna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 792)
DOI
10.1200/JCO.2017.35.4_suppl.792
Abstract #
792
Poster Bd #
N14
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC).
First Author: Alexis Diane Leal
Poster
2016 Gastrointestinal Cancers Symposium
PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.
First Author: Dung T. Le
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
First Author: Michael J. Overman
First Author: Caio Max Sao Pedro Rocha Lima